Developing N-Glycan Diagnostics for Cancer and Infectious Disease

This webinar took place on May 12, 2020

Webinar Overview

Duration: 44 minutes

Alterations in glycosylation have long been associated with the development and progression of many types of chronic and acute diseases.  In this webinar, I will discuss how we have been generating new applications utilizing MALDI Mass Spectrometry Imaging to create innovative solutions to roadblocks in biomarker discovery and clinical assay development.

Key Learning Objectives:

  • How N-linked glycosylation patterns correlate to disease
  • MALDI Imaging reveals disease-state specific N-glycan patterns
  • New strategies for classification of disease
  • How TIMS technology benefits molecular imaging

Who Should Attend

  • Researchers investigating development and/or treatment of disease
  • Researchers interested in gaining deeper understanding of cellular processes in tissues
  • Researchers wanting to expand their knowledge about label-free molecular imaging
  • Researchers wanting to apply label-free imaging to study diseases


Danielle A. Scott Ph.D.
Chief Officer of Product Development at GlycoPath and Visiting Scientist at the Medical University of South Carolina

I am currently the Chief Officer of Product Development at GlycoPath LLC. After finishing my doctorate in the lab of Richard Drake, Ph.D. at the Medical University of South Carolina in four years, I was recruited for the position of Chief Officer of Product Development at GlycoPath. During my doctorate I developed expertise in glycoproteomics and mass spectrometry imaging.I performed my thesis work analyzing changes in N-linked glycosylation in clinical FFPE breast cancer tissues using MALDI-FTICR mass spectrometry imaging. This work resulted in multiple publications and the identification ofa potential biomarker for metastatic breast cancer. My current efforts at GlycoPath have been focused on honing these techniques into the development of clinical diagnostic assays for applications in various cancers and infectious diseases.


For Research Use Only. Not for use in clinical diagnostic procedures.